Market Overview

Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing


On Wednesday, Sterne Agee initiated coverage on shares of Teva Pharmaceutical Industries (NYSE: TEVA) with a Neutral rating and $53 price target.

Analyst Shibani Malhotra believes “strong conversion of Copaxone 20mg/ml to its 40mg/ml formulation is crucial.”

The analyst credits the stocks year-to-date outperformance (up 25 percent) to the company “signaling its willingness to consider a ‘transformational deal.'”

Shibani would prefer “to see management focus on execution of its realignment and cost-cutting strategy before embarking on any ambitious M&A.”

The stock is up one percent to $50.10 in Wednesday's trading.

Latest Ratings for TEVA

Jun 2019Initiates Coverage OnUnderweight
Jun 2019UpgradesPerformOutperform
May 2019DowngradesBuyUnderperform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Shibani Malhotra Sterne AgeeAnalyst Color Analyst Ratings


Related Articles (TEVA)

View Comments and Join the Discussion!

Latest Ratings

RMTIInitiates Coverage On10.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Sterne Agee Sees 16% Upside for Actavis, Initiates Coverage

International ETFs Showing Strength (NGE, EPHE, THD, SPY)